Strategic Developments and Competitive Shifts in Neuroscience
Coverage Period: June 17–July 21, 2026
Introduction
The defining story of this reporting period was the shift from proving therapeutic efficacy to designing neuroscience treatments around the realities of long-term care.
Across Alzheimer’s disease, multiple sclerosis, spinal muscular atrophy, generalized myasthenia gravis, Tourette syndrome, and ADHD, developers advanced treatments differentiated by mechanism, disease stage, dosing frequency, administration setting, and patient eligibility. This matters because neuroscience markets are increasingly shaped by how well a therapy fits into clinical workflows and patient lives. Efficacy remains essential, but competitive advantage may also depend on reducing treatment burden, reaching underserved populations, and supporting adoption beyond controlled trials.
Executive Summary
- Treatment delivery became a central competitive lever. Subcutaneous initiation dosing for lecanemab and proposed quarterly dosing for cemdisiran show how convenience and healthcare-resource use may influence positioning.
- Developers expanded into underserved populations. European approvals in non-relapsing secondary progressive multiple sclerosis and broader spinal muscular atrophy populations extend treatment into areas with limited options.
- Novel neuropsychiatric mechanisms moved closer to commercialization. Ecopipam in pediatric Tourette syndrome and centanafadine in ADHD with comorbid anxiety reflect more targeted differentiation.
- Alzheimer’s disease strategy broadened beyond amyloid. Real-world lecanemab evidence supported the established pathway, while diranersen’s tau reductions provided an early signal for a second disease-modifying mechanism.
- Commercial execution will depend on more than approval. Monitoring, reimbursement, sequencing, infrastructure, and evidence quality will shape market adoption.
Watch the video summary
Our Perspective
Subcutaneous and Infrequent Dosing Reshape Neuroscience Treatment Delivery
The approval of subcutaneous lecanemab for treatment initiation in early Alzheimer’s disease introduces an at-home alternative to intravenous administration. It could reduce reliance on infusion centers, nursing time, and repeated clinic visits.
This matters because the operational burden of anti-amyloid therapy remains a barrier to wider use. Home administration may allow more patients and treatment sites to participate, particularly where infusion capacity is limited, while giving physicians greater flexibility to switch between intravenous and subcutaneous treatment.
Cemdisiran provides a related signal in generalized myasthenia gravis. Its proposed subcutaneous schedule of once every 12 weeks could offer a lower-frequency option in an increasingly competitive targeted-therapy market.
Administration burden is therefore becoming part of the therapeutic value proposition. Products that reduce pressure on specialist infrastructure may gain an advantage even without major efficacy differences.
Key uncertainties: It remains unclear whether greater convenience will improve persistence, expand access, or secure payer recognition. Monitoring requirements, specialty-pharmacy coordination, and reimbursement could still limit uptake.
Multiple Sclerosis and SMA Approvals Expand Treatment Into Later Disease Stages
Recent European approvals in multiple sclerosis and spinal muscular atrophy show the value of extending treatment beyond early or narrowly defined populations.
Tolebrutinib’s approval in secondary progressive multiple sclerosis without recent relapses addresses disability progression in a group with limited disease-modifying options. It also moves therapeutic focus beyond relapse control alone.
The opportunity is tempered by safety management. Drug-induced liver injury is an identified risk, and strict monitoring may affect physician confidence, patient selection, and launch pace. Uptake will depend partly on the effectiveness of risk-management and patient-support programs.
In spinal muscular atrophy, approval of a one-time gene replacement therapy for patients aged two years and older expands the role of gene therapy across the disease course, including for some previously treated patients.
These approvals indicate that lifecycle strategies in progressive neurological disease are extending into broader age groups and later disease stages.
Key uncertainties: Durability, treatment sequencing, affordability, and equitable access remain unresolved. National reimbursement decisions may determine how much of the eligible European population ultimately receives treatment.
Novel Dopamine and Monoamine Approaches Reopen Neuropsychiatry Competition
Progress in Tourette syndrome and ADHD points to renewed interest in differentiated neuropsychiatric therapies.
Ecopipam’s selective dopamine D1 receptor antagonism distinguishes it from approaches centered on D2 signaling. Its US submission could lead to the first newly approved pediatric Tourette syndrome treatment in more than a decade, creating potential value in a market with limited recent innovation.
However, the pivotal trial used a relapse-prevention design in patients who had already responded during open-label treatment. This supports efficacy in a selected population but may limit how broadly the findings apply.
Centanafadine offers another form of differentiation. Its activity across norepinephrine, dopamine, and serotonin pathways may support positioning in adults with ADHD and comorbid anxiety. Positive Phase 3b results across both conditions strengthen the case for a more tailored clinical profile.
The commercial opportunity for both assets will depend on whether mechanistic novelty produces an understandable clinical or tolerability advantage.
Key uncertainties: Prescriber familiarity, payer controls, comparative evidence, and long-term safety will shape adoption. Novel pharmacology alone may not secure durable uptake without a clear benefit in routine care.
Alzheimer’s Disease Strategy Expands From Amyloid Access to Tau Validation
Alzheimer’s disease developments reflected two priorities: improving the delivery and evidence base of an approved anti-amyloid therapy and testing whether tau reduction can generate meaningful clinical benefit.
Subcutaneous lecanemab supports the first priority by making treatment initiation more flexible. Interim LEADER findings also add real-world evidence on persistence, safety, and disease-stage stability across US clinical settings.
The findings require careful interpretation. The study was retrospective, lacked a control group, and assessed broad disease-stage changes rather than pivotal-trial endpoints. It is more useful as an implementation signal than as direct confirmation of treatment effect.
Diranersen addresses the second priority. In Phase 2, the antisense oligonucleotide produced substantial reductions in cerebrospinal-fluid total tau and tau PET measures, alongside favorable findings across several secondary clinical endpoints. This supports further testing of tau reduction and may eventually create opportunities for sequential or combination treatment.
Key uncertainties: The study missed its primary dose-response endpoint, higher doses did not show greater benefit, and one functional measure did not separate from placebo. Phase 3 dose selection, endpoint design, and replication of the clinical signal will determine whether tau becomes a credible second pillar of Alzheimer’s treatment.
What We Are Watching Next
- Final US regulatory decisions and label details for centanafadine and cemdisiran.
- Early European uptake of tolebrutinib and the impact of liver-monitoring requirements.
- Reimbursement and sequencing decisions for expanded gene replacement therapy in SMA.
- Adoption of at-home lecanemab initiation and its effect on infusion capacity, persistence, and access.
- Diranersen’s Phase 3 design, particularly dose selection and functional endpoints.
Key Takeaway
Neuroscience competition is moving beyond whether a therapy works. The stronger strategic question is whether it can reach the right patients, fit into long-term care, reduce treatment burden, and support real-world use.
The developments in this period show that delivery, disease-stage expansion, mechanism, and implementation are becoming closely linked. Therapies that combine meaningful clinical benefit with manageable safety, flexible administration, and credible access pathways may be best positioned to convert regulatory momentum into sustained adoption.
About LucidQuest
LucidQuest helps organizations anticipate change by identifying emerging signals, market shifts, and strategic opportunities.
Contact us at: info@lqventures.com